Adenocarcinoma of Pancreas
Find comprehensive information on Adenocarcinoma of the Pancreas, also known as Pancreatic Cancer or Pancreatic Ductal Adenocarcinoma. This resource offers guidance on healthcare aspects, clinical documentation, and medical coding related to this diagnosis, including ICD-10 codes, SNOMED CT codes, and relevant medical terminology. Learn about diagnosis, treatment options, and prognosis for Adenocarcinoma of Pancreas. This information supports accurate medical record keeping and facilitates effective communication among healthcare professionals.
Cancer originating in the pancreas gland ducts, often aggressively spreading.
Jaundice, abdominal pain, weight loss, nausea, fatigue. May be asymptomatic initially.
Diagnosed in hospitals or specialized cancer centers through imaging (CT, MRI) and biopsies.
ICD-10 Code Families
Complete code families applicable to C25.9
When to use each related code
| Description | When to use |
|---|---|
| Cancer of the pancreas exocrine glands. | Use for malignant tumors of the pancreas originating in the ducts. Most common type of pancreatic cancer. |
| Rare neuroendocrine tumor of the pancreas. | Use for pancreatic tumors arising from islet cells. Often functional, secreting hormones like insulin or gastrin. |
| Cystic neoplasm of the pancreas. | Use for precancerous or cancerous cysts in the pancreas. Includes serous and mucinous types. |
Best-practice checklist
- ✓Pancreatic adenocarcinoma diagnosis: Document primary site
- ✓Adenocarcinoma of pancreas: Note TNM stage, grade
- ✓Pancreatic cancer: Include laterality (right, left, head, body, tail)
- ✓Document CA 19-9 levels, imaging results (CT, MRI, PET)
- ✓Pancreatic ductal adenocarcinoma: Specify if metastatic disease present
Common pitfalls to avoid
Coding requires precise histology; 'adenocarcinoma' needs further specification if known (e.g., acinar, mucinous) to avoid upcoding/downcoding.
Documenting the origin within the pancreas (head, body, tail) is crucial for accurate staging and coding, impacting reimbursement.
While less common for pancreas, laterality (if applicable) should be documented to prevent coding errors and ensure complete clinical data.
Best-practice tips
- 01Code C25.0-C25.9 for pancreatic adenocarcinoma, ensuring ICD-10-CM compliance.
- 02Document tumor size, location, and differentiation for accurate staging and reimbursement.
- 03Query physicians for clarity on ambiguous diagnoses like pancreatic mass vs. cancer.
- 04Abstract histology reports meticulously for correct coding and cancer registry data.
- 05Regularly audit pancreatic cancer cases for CDI to optimize coding accuracy and revenue.
Step-by-step checklist
- 1
Verify imaging (CT/MRI/PET) confirms pancreatic mass.
- 2
Confirm histopathology report shows adenocarcinoma.
- 3
Check CA 19-9 levels (if obtained).
- 4
Document TNM stage based on imaging and pathology.
- 5
Assess for resectability and document rationale.
Ready-to-paste narrative
Patient presents with concerning signs and symptoms suggestive of adenocarcinoma of the pancreas, also referred to as pancreatic cancer or pancreatic ductal adenocarcinoma. Presenting complaints include persistent abdominal pain radiating to the back, unexplained weight loss, jaundice, new-onset diabetes, loss of appetite, fatigue, and changes in stool. Physical examination may reveal abdominal tenderness, palpable mass, and signs of jaundice. Differential diagnoses include chronic pancreatitis, pancreatic cysts, and other gastrointestinal malignancies. Initial workup includes laboratory tests such as liver function tests, complete blood count, CA 19-9 tumor marker, and imaging studies including abdominal ultrasound, CT scan of the abdomen and pelvis with contrast, and endoscopic ultrasound with fine needle aspiration for tissue biopsy if indicated. Diagnostic criteria for adenocarcinoma of the pancreas rely on histopathological confirmation from biopsy specimens. Staging of the disease will be determined based on imaging and potentially surgical exploration, considering factors such as tumor size, lymph node involvement, and distant metastasis. Treatment plan discussions will involve a multidisciplinary approach, including medical oncology, surgical oncology, radiation oncology, gastroenterology, and palliative care, and may encompass surgical resection (Whipple procedure or distal pancreatectomy), chemotherapy, radiation therapy, targeted therapy, pain management, and supportive care. Prognosis and survival rates for pancreatic adenocarcinoma vary depending on the stage at diagnosis and response to treatment. Patient education regarding the disease process, treatment options, potential complications, and palliative care options is crucial. Follow-up care will include regular monitoring of tumor markers, imaging studies, and symptom management. ICD-10 code C25.9 (malignant neoplasm of pancreas, unspecified) and relevant CPT codes for procedures performed will be documented for accurate medical billing and coding purposes.
Common questions and answers
What are the most effective current treatment strategies for locally advanced unresectable pancreatic adenocarcinoma, considering patient performance status and comorbidities?+
Treatment for locally advanced unresectable pancreatic adenocarcinoma requires a multidisciplinary approach tailored to individual patient characteristics, including performance status and comorbidities. While surgery is not an option in these cases, neoadjuvant chemotherapy, particularly FOLFIRINOX (if the patient's performance status allows), or gemcitabine/nab-paclitaxel, is often the preferred initial approach. These regimens aim to shrink the tumor and potentially make it resectable. Radiation therapy, including stereotactic body radiotherapy (SBRT) or conventional external beam radiation, can be added concurrently or sequentially with chemotherapy, especially for pain control or local tumor control. For patients with borderline resectable disease, aggressive neoadjuvant therapy may enable subsequent surgery. Supportive care, including pain management, nutritional support, and management of other comorbidities, is crucial throughout the treatment course. Explore how molecular profiling can further personalize treatment strategies. Consider implementing a multidisciplinary tumor board review for each patient to optimize treatment decisions.
How can I differentiate between chronic pancreatitis and pancreatic adenocarcinoma based on imaging findings (CT, MRI) and CA 19-9 levels, and when is endoscopic ultrasound with fine needle aspiration (EUS-FNA) indicated for definitive diagnosis?+
Differentiating chronic pancreatitis from pancreatic adenocarcinoma can be challenging, as imaging and CA 19-9 levels can sometimes overlap. While both conditions may present with pancreatic ductal dilation and parenchymal changes on CT or MRI, features suggestive of adenocarcinoma include a focal mass, irregular margins, and vascular involvement. Elevated CA 19-9 levels are more strongly associated with adenocarcinoma, but they are not diagnostic, and some pancreatic cancers can present with normal CA 19-9. Chronic pancreatitis may show calcifications, pseudocysts, and a more diffuse pattern of changes. When imaging and CA 19-9 are inconclusive, endoscopic ultrasound with fine needle aspiration (EUS-FNA) is the gold standard for obtaining tissue for pathological diagnosis and is crucial for differentiating between the two conditions. EUS-FNA allows for accurate sampling and avoids the risks associated with more invasive procedures. Learn more about the specific imaging features that help differentiate between these two conditions.
What emerging targeted therapies and immunotherapies show promise in treating metastatic pancreatic adenocarcinoma, particularly for patients who have progressed on first-line chemotherapy regimens like FOLFIRINOX or gemcitabine/nab-paclitaxel?+
While systemic chemotherapy remains the mainstay of treatment for metastatic pancreatic adenocarcinoma, research into targeted therapies and immunotherapies is ongoing. For patients who progress on first-line FOLFIRINOX or gemcitabine/nab-paclitaxel, options are limited, but some targeted therapies may be considered based on molecular profiling. For instance, patients with BRCA mutations or other DNA damage repair pathway deficiencies may benefit from PARP inhibitors like olaparib or rucaparib. Unfortunately, immunotherapy has shown limited efficacy in unselected pancreatic cancer patients, likely due to the immunosuppressive tumor microenvironment. However, ongoing research is exploring strategies to overcome this resistance, such as combining immunotherapy with chemotherapy or targeted therapies. Clinical trials are crucial for evaluating these novel therapeutic approaches and should be considered for eligible patients. Consider implementing molecular profiling early in the disease course to identify potential targets for personalized therapy.
Clinical accuracy: This information is provided for documentation and coding guidance and should not replace professional medical judgment.
Coding standard: ICD-10-CM, current FY guidelines.